Breast Ultrasound Versus MRI in Prediction of Pathologic Complete Response to Neoadjuvant Chemotherapy for Breast Cancer: A Systematic Review and Meta-Analysis
Authors:
- 14 October 2020
- journal article
- review article
- Published by SAGE Publications in Journal of Diagnostic Medical Sonography
- Vol. 37 (1) , 47-57
Abstract
Introduction: Neoadjuvant chemotherapy (NAC) is widely used to treat breast cancer. Sentinel lymph node biopsy has replaced axillary lymph node dissection in patients who convert to node-negative status, after NAC. However, few studies have evaluated the diagnostic performance of ultrasonography (US) and magnetic resonance imaging (MRI) in determining axillary lymph node status after NAC. The aim of this study was to evaluate the diagnostic performance of breast US and MRI in predicting a response to NAC, for breast cancer. Methods: A systematic search, in PubMed, the Cochrane Library, and Web of Science, for original studies was performed. The Quality Assessment of Diagnostic Accuracy Studies 2 tool was used to assess the methodological quality of the included studies. Patient, study, and imaging characteristics were extracted, and sufficient data were used to reconstruct 2 × 2 tables. Data pooling, heterogeneity testing, forest plot construction, meta-regression analysis, and sensitivity analysis were performed using Meta-DiSc and Stata version 14.0 (StataCorp LP, College Station, TX, USA). Results: Nine studies met all the eligibility criteria and were included. The pooled sensitivity and specificity of MRI were 0.78 and 0.92, while the corresponding values for US were 0.80 and 0.90, respectively. The prevalence of pathologic complete response (pCR), among breast cancer patients, after neoadjuvant therapy was 26%. The prevalence of patients with estrogen receptor (ER)-, human epidermal growth factor receptor (HER)-, and progesterone receptor (PR)-positive tumors were 65%, 22%, and 37%, respectively. Conclusion: These results showed that MRI and US have almost the same accuracy in predicting pCR in patients with breast cancer undergoing neoadjuvant surgery. There is still a need for further investigations to prove that US is not inferior to MRI for this diagnosis.Keywords
This publication has 29 references indexed in Scilit:
- Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysisClinical Breast Cancer, 2017
- Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer SubtypeThe Oncologist, 2017
- Multi-parametric MRI in the early prediction of response to neo-adjuvant chemotherapy in breast cancer: Value of non-modelled parametersEuropean Journal of Radiology, 2016
- Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancerEuropean Journal of Cancer, 2015
- Comparison of the diagnostic performance of digital breast tomosynthesis and magnetic resonance imaging added to digital mammography in women with known breast cancersEuropean Radiology, 2015
- Comparative accuracy of preoperative tumor size assessment on mammography, sonography, and MRI: Is the accuracy affected by breast density or cancer subtype?Journal of Clinical Ultrasound, 2015
- Breast MRI: EUSOBI recommendations for women’s informationEuropean Radiology, 2015
- Prospective Trial of Breast MRI Versus 2D and 3D Ultrasound for Evaluation of Response to Neoadjuvant ChemotherapyAnnals of Surgical Oncology, 2015
- Wertigkeit von Mammographie, Sonographie und MRT zur Verlaufsbeurteilung der neoadjuvanten Chemotherapie bei lokal fortgeschrittenem MammakarzinomDer Radiologe, 2010
- Contrast-enhanced US and MRI for assessing the response of breast cancer to neoadjuvant chemotherapyJournal of Ultrasound, 2008